This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schülin, T.
Right arrow Articles by Eliopoulos, G. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schülin, T.
Right arrow Articles by Eliopoulos, G. M.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, June 1998, p. 1520-1523, Vol. 42, No. 6
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Susceptibilities of Legionella spp. to Newer Antimicrobials In Vitro

T. Schülin,1,2 C. B. Wennersten,1 M. J. Ferraro,2,3 R. C. Moellering Jr.,1,2 and G. M. Eliopoulos1,2,*

Department of Medicine, West Campus, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215,1 Harvard Medical School, Boston, Massachusetts 02115,2 and Massachusetts General Hospital, Boston, Massachusetts 021143

Received 17 November 1997/Returned for modification 26 February 1998/Accepted 1 April 1998

The in vitro activities of 13 antimicrobial agents against 30 strains of Legionella spp. were determined. Rifapentine, rifampin, and clarithromycin were the most potent agents (MICs at which 90% of isolates are inhibited [MIC90s], <= 0.008 µg/ml). The ketolide HMR 3647 and the fluoroquinolones levofloxacin and BAY 12-8039 (MIC90s, 0.03 to 0.06 µg/ml) were more active than erythromycin A or roxithromycin. The MIC90s of dalfopristin-quinupristin and linezolid were 0.5 and 8 µg/ml, respectively. Based on class characteristics and in vitro activities, several of these agents may have potential roles in the treatment of Legionella infections.

* Corresponding author. Mailing address: Department of Medicine---West Campus, Beth Israel Deaconess Medical Center, One Deaconess Rd., Boston, MA 02215. Phone: (617) 632-8586. Fax: (617) 632-7442. E-mail: geliopou{at}bidmc.harvard.edu.

Antimicrobial Agents and Chemotherapy, June 1998, p. 1520-1523, Vol. 42, No. 6
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Lim, W S, Baudouin, S V, George, R C, Hill, A T, Jamieson, C, Le Jeune, I, Macfarlane, J T, Read, R C, Roberts, H J, Levy, M L, Wani, M, Woodhead, M A, Pneumonia Guidelines Committee of the BTS Standard, (2009). BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 64: iii1-iii55 [Full Text]  
  • Kim, D.-M., Yu, K. D., Lee, J. H., Kim, H. K., Lee, S.-H. (2007). Controlled Trial of a 5-Day Course of Telithromycin versus Doxycycline for Treatment of Mild to Moderate Scrub Typhus. Antimicrob. Agents Chemother. 51: 2011-2015 [Abstract] [Full Text]  
  • Dorbecker, C., Sander, A., Oberle, K., Schulin-Casonato, T. (2006). In vitro susceptibility of Bartonella species to 17 antimicrobial compounds: comparison of Etest and agar dilution. J Antimicrob Chemother 58: 784-788 [Abstract] [Full Text]  
  • Sabria, M., Pedro-Botet, M. L., Gomez, J., Roig, J., Vilaseca, B., Sopena, N., Banos, V., for the Legionnaires Disease Therapy Group, (2005). Fluoroquinolones vs Macrolides in the Treatment of Legionnaires Disease. Chest 128: 1401-1405 [Abstract] [Full Text]  
  • Roch, N., Maurin, M. (2005). Antibiotic susceptibilities of Legionella pneumophila strain Paris in THP-1 cells as determined by real-time PCR assay. J Antimicrob Chemother 55: 866-871 [Abstract] [Full Text]  
  • Clark, J. P., Langston, E. (2003). Ketolides: A New Class of Antibacterial Agents for Treatment of Community-Acquired Respiratory Tract Infections in a Primary Care Setting. Mayo Clin Proc. 78: 1113-1124 [Abstract]  
  • Maurin, M., Bryskier, A., Raoult, D. (2002). Antibiotic Susceptibilities of Parachlamydia acanthamoeba in Amoebae. Antimicrob. Agents Chemother. 46: 3065-3067 [Abstract] [Full Text]  
  • Kadota, J.-I., Ishimatsu, Y., Iwashita, T., Matsubara, Y., Tomono, K., Tateno, M., Ishihara, R., Muller-Serieys, C., Kohno, S. (2002). Intrapulmonary Pharmacokinetics of Telithromycin, a New Ketolide, in Healthy Japanese Volunteers. Antimicrob. Agents Chemother. 46: 917-921 [Abstract] [Full Text]  
  • (2001). BTS Guidelines for the Management of Community Acquired Pneumonia in Adults. Thorax 56: iv1-64 [Full Text]  
  • Muller-Serieys, C., Soler, P., Cantalloube, C., Lemaitre, F., Gia, H. P., Brunner, F., Andremont, A. (2001). Bronchopulmonary Disposition of the Ketolide Telithromycin (HMR 3647). Antimicrob. Agents Chemother. 45: 3104-3108 [Abstract] [Full Text]  
  • Jonas, D., Engels, I., Friedhoff, C., Spitzmuller, B., Daschner, F. D., Frank, U. (2001). Efficacy of moxifloxacin, trovafloxacin, clinafloxacin and levofloxacin against intracellular Legionella pneumophila. J Antimicrob Chemother 47: 147-152 [Abstract] [Full Text]  
  • Rolain, J.-M., Maurin, M., Raoult, D. (2001). Bacteriostatic and Bactericidal Activities of Moxifloxacin against Coxiella burnetii. Antimicrob. Agents Chemother. 45: 301-302 [Abstract] [Full Text]  
  • Maurin, M., Mersali, N. F., Raoult, D. (2000). Bactericidal Activities of Antibiotics against Intracellular Francisella tularensis. Antimicrob. Agents Chemother. 44: 3428-3431 [Abstract] [Full Text]  
  • Rastogi, N., Goh, K. S., Berchel, M., Bryskier, A. (2000). In Vitro Activities of the Ketolides Telithromycin (HMR 3647) and HMR 3004 Compared to Those of Clarithromycin against Slowly Growing Mycobacteria at pHs 6.8 and 7.4. Antimicrob. Agents Chemother. 44: 2848-2852 [Abstract] [Full Text]  
  • Gustafsson, I., Hjelm, E., Cars, O. (2000). In Vitro Pharmacodynamics of the New Ketolides HMR 3004 and HMR 3647 (Telithromycin) against Chlamydia pneumoniae. Antimicrob. Agents Chemother. 44: 1846-1849 [Abstract] [Full Text]  
  • Rolain, J.-M., Maurin, M., Bryskier, A., Raoult, D. (2000). In Vitro Activities of Telithromycin (HMR 3647) against Rickettsia rickettsii, Rickettsia conorii, Rickettsia africae, Rickettsia typhi, Rickettsia prowazekii, Coxiella burnetii, Bartonella henselae, Bartonella quintana, Bartonella bacilliformis, and Ehrlichia chaffeensis. Antimicrob. Agents Chemother. 44: 1391-1393 [Abstract] [Full Text]  
  • Padayachee, T., Klugman, K. P. (1999). Molecular Basis of Rifampin Resistance in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 43: 2361-2365 [Abstract] [Full Text]  
  • Dedicoat, M., Venkatesan, P. (1999). The treatment of Legionnaires' disease. J Antimicrob Chemother 43: 747-752 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»